33 Clinical Trials on Olive Oil: The Result Nobody Talks About
Everyone says olive oil is “heart-healthy.” But when researchers pooled 33 randomised controlled trials and 2,020 participants, the results were more nuanced than the headline. EVOO moved insulin resistance — significantly, reproducibly, and with zero heterogeneity in one key outcome. But it didn’t budge cholesterol, blood pressure, or C-reactive protein. What does that actually tell us about how olive oil works in the body?
01 The Inconvenient Nuance
Walk into any supermarket, and you’ll see olive oil marketed as a cholesterol-lowering, heart-protecting, inflammation-fighting superfood. The evidence for these claims exists — but much of it comes from large cohort studies, dietary pattern research, and the PREDIMED trial, which tested an entire Mediterranean dietary pattern against a low-fat control diet. When you strip all of that away and isolate EVOO as a single intervention in controlled clinical trials, the picture gets more interesting.
That is precisely what Morvaridzadeh et al. set out to do. Their 2024 systematic review and meta-analysis, published in The Journal of Nutrition — one of the oldest and most prestigious nutrition journals in the world — pooled every randomised controlled trial (RCT) that tested EVOO in isolation against a control condition. The question: which biomarkers actually move when you add EVOO to someone’s diet in a controlled setting?
The answer is simultaneously more modest and more specific than the marketing would suggest — and it tells us something important about how olive oil actually works.
02 Study Overview
Publication
- Journal: The Journal of Nutrition (J Nutr), 2024 Jan; 154(1):95–120
- Authors: Morvaridzadeh M et al.
- DOI: 10.1016/j.tjnut.2023.10.028
- PMID: 37977313
- PROSPERO: CRD42023409125
- Study type: Systematic review + meta-analysis of RCTs
Methodology
- Databases: PubMed/MEDLINE, Scopus, Cochrane (through March 2023)
- Studies included: 33 RCTs
- Participants: 2,020 total
- Effect measure: Standardised mean difference (Hedge’s g), random-effects model
- Heterogeneity: Cochran Q-statistic + I²
- Language: No restriction
Outcomes Measured
Insulin, HOMA-IR, fasting blood glucose, triglycerides, total cholesterol, LDL, VLDL, HDL, ApoA-I, ApoB, lipoprotein-a, systolic and diastolic blood pressure, BMI, waist circumference, waist-to-hip ratio, C-reactive protein (CRP), interleukin-6 (IL-6), interleukin-10 (IL-10), tumour necrosis factor-α (TNF-α).
03 Key Findings — The Actual Numbers
What EVOO Significantly Changed
Two outcomes reached statistical significance across the pooled trials:
Serum Insulin
SMD: −0.28 | 95% CI: −0.51 to −0.05 | I² = 48.57%
Drawn from 10 trials, EVOO consumption was associated with a statistically significant reduction in fasting serum insulin compared to control. A standardised mean difference of −0.28 represents a small-to-moderate effect size — meaningful in a population context. The I² of 48.57% suggests moderate heterogeneity, meaning results varied somewhat across trials (likely due to differences in baseline insulin levels, dose, and duration).
HOMA-IR (Insulin Resistance)
SMD: −0.19 | 95% CI: −0.35 to −0.03 | I² = 0.00%
This is the headline result of the study. Across 9 trials, EVOO produced a statistically significant reduction in HOMA-IR — the standard clinical measure of insulin resistance — with essentially zero heterogeneity (I² = 0.00%). In meta-analysis methodology, that’s exceptional. It means the effect was consistent across different study populations, designs, and doses. You don’t get I² = 0% on a random collection of trials. You get it when there’s a real, reproducible biological signal.
What EVOO Did NOT Significantly Change
This is the part that rarely makes it into the health media headlines:
All P > 0.05 in random-effects meta-analysis
Let that sink in. Across 33 controlled clinical trials, EVOO did not significantly move cholesterol, blood pressure, CRP, or body weight compared to control. This contradicts the common marketing claim that olive oil is a direct cholesterol-lowering agent.
Advertisement
04 The Biological Mechanism — How Does EVOO Improve Insulin Sensitivity?
The selective effect on insulin resistance — while leaving cholesterol and blood pressure untouched — is not a statistical artefact. It maps directly onto what we know about EVOO’s biochemistry.
Oleic Acid and PPAR-γ Activation
EVOO is 55–83% oleic acid (C18:1), a monounsaturated fatty acid that activates peroxisome proliferator-activated receptor gamma (PPAR-γ) — the same nuclear receptor targeted by the thiazolidinedione class of diabetes medications. PPAR-γ activation enhances insulin receptor signalling in adipose and muscle tissue, increasing GLUT4 translocation to the cell surface and improving glucose uptake without requiring more insulin. This explains why insulin goes down even when glucose stays the same: cells become more responsive, so the pancreas secretes less.
Oleocanthal and IRS-1 Phosphorylation
Oleocanthal — the secoiridoid responsible for olive oil’s characteristic throat-sting — has been shown to increase insulin receptor substrate-1 (IRS-1) tyrosine phosphorylation in skeletal muscle cells. IRS-1 is the first downstream effector of the insulin receptor; better phosphorylation means better signal transduction. Laboratory data from Abuznait et al. (2013, ACS Chemical Neuroscience) demonstrated oleocanthal’s ability to enhance insulin signalling independent of receptor binding — a meaningful mechanistic contribution to the clinical findings.
Hydroxytyrosol and Mitochondrial Biogenesis
Hydroxytyrosol — arguably EVOO’s most potent polyphenol — activates AMPK (AMP-activated protein kinase) and PGC-1α, the master regulator of mitochondrial biogenesis. Dysfunctional mitochondria in skeletal muscle are a root cause of peripheral insulin resistance. By increasing mitochondrial number and efficiency, hydroxytyrosol helps muscle cells burn more glucose via oxidative phosphorylation, reducing the glucose load that demands an insulin response. This mechanism is distinct from any effect on cholesterol synthesis, which explains why lipid panels remain largely unchanged.
Why Cholesterol Doesn’t Move in RCTs
The observational evidence linking Mediterranean diets to better lipid profiles is real — but in those studies, EVOO replaces saturated fat. When you run an RCT that compares EVOO against refined vegetable oil or another unsaturated fat, you lose the contrast. The comparison group is also relatively “good” — cholesterol doesn’t budge because both groups are eating unsaturated fats. It’s not that EVOO fails to help; it’s that the RCT design underestimates the benefit by choosing an unfair control.
05 Context — What Previous Research Shows
The insulin-sensitising effect found here aligns with a growing body of mechanistic and clinical evidence. A 2017 meta-analysis by Schwingshackl et al. in Nutrition & Metabolism found Mediterranean diets significantly reduced HbA1c and fasting glucose in type 2 diabetics — but the dietary pattern included many other foods. The Morvaridzadeh 2024 paper is notable precisely because it isolates EVOO as the single variable, stripping away legumes, fish, nuts, and vegetables to ask: what does the oil itself do?
The finding on CRP is worth contextualising. Our previous coverage of Zhou et al. (2026) on kidney disease found that high-phenolic EVOO significantly reduced CRP in CKD patients (by 0.79 mg/L). The Morvaridzadeh analysis did not stratify by polyphenol content. This may explain the null CRP result — if a proportion of the 33 included trials used low-polyphenol olive oil (which is common in supermarkets), the anti-inflammatory signal would be diluted or lost entirely.
Francesco Visioli — one of the world’s leading olive oil researchers — published a pointed editorial accompanying this meta-analysis in the same issue of The Journal of Nutrition, titled “The Question of Cholesterol: Will Olive Oil Answer?” (PMID: 38040408). His argument: we keep expecting EVOO to act like a statin when its mechanisms are fundamentally different. The metabolic pathway runs through insulin sensitivity and oxidative stress, not HMG-CoA reductase inhibition.
06 Practical Takeaway — What Should You Actually Do?
Use EVOO as a fat substitute, not an additive.
The insulin-sensitising benefit was seen when olive oil replaced other dietary fats. Adding it on top of an existing diet dominated by saturated or refined vegetable oils is unlikely to produce the same effect. The studies that showed results used EVOO as the primary cooking and dressing fat.
Dose: 20–50 mL/day appears to be the effective range.
The included trials used varying doses, but most saw metabolic benefit at 20–50 mL daily (roughly 1.5–3.5 tablespoons). That’s achievable through cooking, salad dressings, and morning spoonfuls — but requires intentionality.
Don’t use this study to stop monitoring cholesterol.
The null result on lipid panels means EVOO is not a substitute for medical management of hypercholesterolaemia. It reduces the insulin-driven component of cardiovascular risk, but won’t drop your LDL by 30 mg/dL. Those are different problems requiring different tools.
Polyphenol content likely matters enormously — but we don’t yet have the data.
The CRP-reducing effect found in the CKD meta-analysis (Zhou 2026) was specific to high-phenolic EVOO. The metabolic effects may also be dose-dependent on polyphenol concentration. Until trials specifically compare high-phenolic vs. standard EVOO on insulin markers, the safest bet is to choose an oil with verified polyphenol content above 500 mg/kg.
07 Limitations — What This Study Cannot Tell Us
Moderate heterogeneity in the insulin outcome
The insulin reduction had I² = 48.57%, indicating moderate between-study variability. While significant overall, individual trial effects varied — some showed stronger reductions, others near-zero. This means the average effect of −0.28 SMD may not apply uniformly across populations. Subgroup analysis by baseline insulin level, diabetes status, and intervention dose is needed.
Polyphenol content not standardised
None of the 33 trials used a standardised, verified EVOO with declared polyphenol content. Oils ranged from commercial supermarket EVOO to artisanal high-phenolic products. This is a critical limitation — the biological dose of hydroxytyrosol and oleocanthal in each trial is unknown, making it impossible to determine whether higher-phenolic oils produce stronger effects.
Short intervention durations
Most included trials ran for 4–16 weeks. Insulin resistance is a chronic metabolic condition that takes years to develop and decades to reverse. Whether 4 weeks of EVOO consumption produces a clinically durable reduction in HOMA-IR — or whether it reverts when the intervention stops — is unknown. Long-term follow-up data are lacking.
Control group comparability
As noted, the null results on cholesterol may partly reflect control groups consuming other unsaturated fats. A stricter control — replacing EVOO with butter or lard — would likely show larger effects. This is an inherent limitation of dietary fat RCTs rather than a flaw in the analysis itself.
Funding sources
The authors do not report conflicts of interest. The study was registered in PROSPERO (CRD42023409125), indicating pre-specified methodology — which is a mark of quality. However, many of the included trials were funded by olive oil industry bodies, which is a confounding factor common to this literature.
08 Our Take — Is This Study Strong? Weak? Game-Changing?
This is a methodologically solid meta-analysis published in a serious journal, with pre-registered methodology and a broad literature search. It’s not groundbreaking in the way that PREDIMED was — it doesn’t tell us EVOO prevents heart attacks. What it does is clarify a specific mechanism with more precision than previous work.
The I² = 0% on HOMA-IR is genuinely noteworthy. In nutritional intervention trials, getting zero heterogeneity across 9 studies is rare. It suggests the insulin-sensitising effect is not driven by one outlier study, not confounded by population differences, and not an artefact of publication bias. It’s a real, consistent signal.
The null results on cholesterol, CRP, and blood pressure should be read carefully — not as “olive oil doesn’t help the heart” but as “olive oil helps the heart via a different pathway than we assumed.” Insulin resistance is an upstream driver of both cardiovascular disease and type 2 diabetes. Reducing HOMA-IR means you’re addressing root-cause metabolic dysfunction, not just treating a biomarker.
The limitation we care most about: polyphenol content is unknown across the 33 trials. We know from other research (Zhou 2026, PREDIMED-Plus data) that the anti-inflammatory benefits of EVOO are polyphenol-dependent. If the insulin-sensitising effect is also polyphenol-dependent — which the oleocanthal mechanism suggests it might be — then the true effect of high-phenolic EVOO on HOMA-IR could be substantially larger than −0.19 SMD. That’s the study we’re still waiting for.
09 References
Morvaridzadeh M, et al. “Effect of Extra Virgin Olive Oil on Anthropometric Indices, Inflammatory and Cardiometabolic Markers: a Systematic Review and Meta-Analysis of Randomized Clinical Trials.” The Journal of Nutrition. 2024 Jan;154(1):95–120. doi: 10.1016/j.tjnut.2023.10.028. PMID: 37977313.
View on PubMed →Visioli F. “The Question of Cholesterol: Will Olive Oil Answer?” J Nutr. 2024 Jan;154(1):10–11. doi: 10.1016/j.tjnut.2023.11.019. PMID: 38040408.
Abuznait AH, et al. “Olive-Oil-Derived Oleocanthal Enhances β-Amyloid Clearance as a Potential Neuroprotective Mechanism against Alzheimer’s Disease.” ACS Chem Neurosci. 2013;4(6):973–982. doi: 10.1021/cn400024q.
Zhou M et al. “High-phenolic olive oil reduces CRP and improves eGFR in CKD patients.” Front Nutr. 2026. PMID: 41847236.
EU Commission Regulation (EU) No 432/2012 — establishing the health claim for olive oil polyphenols on oxidative stress protection of blood lipids.
Looking for an EVOO with verified high polyphenol content?
View Our Lab-Tested Rankings →